NeuroPace vs Neuronetics
NPCE and STIM side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NPCE and STIM compare
NeuroPace is the larger company, worth 3.8 times as much as Neuronetics ($413M against $109M).
Neuronetics grew revenue faster over the last twelve months (23.0% versus 23.0% for NeuroPace).
Neuronetics keeps more of each dollar of sales as profit, with a net margin of −14.4% compared with −17.7% at NeuroPace.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NPCE | STIM |
|---|---|---|
| Size and price | ||
| Market cap | $413M | $109M |
| Share price | $12.02 | $1.43 |
| Change, 1 year | −10.9% | −35.0% |
| Change, 5 years | 1.4% | −64.3% |
| Beta (5Y) | 1.05 | 1.57 |
| Employees | 209 | 658 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 0 |
| Growth score | 3 | 3 |
| Performance score | 1 | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.9× | 0.7× (better) |
| P/B | 35.9× | 5.8× (better) |
| FCF yield | −3.0% (better) | −8.8% |
| Fair value | $6.78 | – |
| Margin of safety | −77.2% | – |
| Growth | ||
| Revenue growth (TTM) | 23.0% | 23.0% (better) |
| Revenue growth, 5Y average | 19.4% | 24.8% (better) |
| Profitability | ||
| Gross margin | 77.8% (better) | 50.7% |
| Operating margin | −9.5% | −9.4% (better) |
| Net margin | −17.7% | −14.4% (better) |
| FCF margin | −11.6% | −6.0% (better) |
| Return on equity | −126% | −100% (better) |
| Return on invested capital | −41.4% | −19.2% (better) |
| Financial health | ||
| Debt / equity | 5.15 | 3.30 (better) |
| Interest coverage | −1.6× (better) | −1.7× |
| Current ratio | 5.26 (better) | 2.01 |
| Altman Z-score | −3.79 | −3.36 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 77.4% | 48.8% |
| Held by insiders | 16.6% | 51.3% |
| Insider net buying, 12 months | −$399K | $4.6M (better) |
| Short interest, % of float | 3.0% | 18.0% |
Go deeper
- NPCE stock overview
- NPCE income statement
- NPCE valuation and score
- STIM stock overview
- STIM income statement
- STIM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.